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934Role of aneurysm sac embolization during
endovascular aneurysm repair in the prevention
of type II endoleak-related complications
Michele Piazza, MD,a Paolo Frigatti, MD,c Paolo Scrivere, MD,a Stefano Bonvini, MD, PhD,a
Franco Noventa, MD,b Joseph J. Ricotta II, MD, MS,d Franco Grego, MD,a and
Michele Antonello, MD, PhD,a Padova and Udine, Italy; and Atlanta, Ga
Objective: The goal of this study was to evaluate the role of intraoperative aneurysm sac embolization during endovascular
aneurysm repair (EVAR) using a standard dose of coils and ﬁbrin glue in the prevention of type II endoleak (EII).
Methods: Two groups were compared: 83 patients underwent standard EVAR during the period 2008-2009 (group A)
and 79 patients underwent EVAR during the period 2010-2011 (group B). Computed tomography scans were evaluated
with Osirix Pro 4.0 software to obtain aneurysm sac volume. EII rates at the ﬁrst computed tomography scan follow-up,
as well as midterm freedom from EII and freedom from related reintervention, were compared. Preoperative number of
patent aortic side branches (inferior mesenteric artery, lumbar arteries, accessory renal arteries), sac thrombus, and sac
volume were evaluated for their association with EII in the two groups using multiple logistic regressions.
Results: Patient characteristics, Society for Vascular Surgery comorbidity scores (0.85 ± 0.44 vs 0.82 ± 0.46; P [ .96),
and operative time (185 ± 52 vs 179 ± 49; P[ .92) were similar for groups A and B. The ﬁrst computed tomography scan
(#3 months) revealed a signiﬁcantly larger number of EIIs in group A than in group B (23% vs 10%; P [ .02). Spon-
taneous EII resolution occurred in 65% of patients in group A and in 79% in group B (P [ 1.0), whereas sac volume
increased in 25% and 10% (P [ .63) of cases, respectively. At 18 months (range, 6 months to 4.4 years), overall mean
differences in sac volume shrinkage (27 ± 12 cm3 vs 25 ± 12 cm3; P[ .19) and freedom from EII (92% vs 96%; P[ .33)
were similar, whereas freedom from reintervention was signiﬁcantly lower in group A (93% vs 99%; P [ .03) than in
group B. Multivariate analysis showed preoperative aneurysm sac volume >125 cm3 to be the only independent signiﬁcant
predictor of EII (odds ratio, 4.0; 95% conﬁdence interval, 1.5-10.5; P [ .005).
Conclusions: Although further conﬁrmatory studies are needed, sac embolization during EVARmay be a valid approach to
preventing EII and its complications during short- and midterm follow-up. More aggressive intraoperative embolization
should be considered for patients with a preoperative aneurysm sac volume >125 cm3. (J Vasc Surg 2013;57:934-41.)Type II endoleak (EII) occurs in about 10% to 30% of
patients after endovascular aneurysm repair (EVAR),
because of retrograde ﬂow from aortic side-branch vessels
into the abdominal aortic aneurysm (AAA) sac.1,2 Most
types of EII are innocuous and resolve spontaneously after
a variable period, but those with a persistent mechanism of
inﬂow-outﬂow between patent branches and the sac could
cause signiﬁcant aneurysm sac enlargement or be persis-
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://dx.doi.org/10.1016/j.jvs.2012.10.078of adverse outcomes.3,4 Secondary interventions such as
transarterial embolization and endoscopic ligation of the
feeding branches, direct sac puncture, and aneurysm sac
plication are reported in about 10% of cases5,6; the need
for surgical reconstruction with endograft explantation is
rare.
The additional medical expenses incurred for these addi-
tional procedures, as well as the increased exposure of
patients to radiation and contrast agents during follow-up,
represent a limitation to EVAR and occasionally can lead
to a waste of its advantages in terms of costs and clinical
success.
In this scenario, prevention of EII formation could be
a valid strategy limiting this complication; previous reports
have indicated that injection of ﬁbrin glue alone or in asso-
ciation with microcoils into the aneurysmal sac during
EVAR can facilitate sac thrombosis and reduce the inci-
dence of EII.7,8 However, the exact dose of material
needed to effectively prevent this complication has not
yet been standardized, and no reliable preoperative predic-
tive parameters are currently available.
The purpose of this study was to review our experience
in the treatment of AAAs by aneurysm sac embolization
during EVAR (embo-EVAR) using a standard dose of
ﬁbrin glue and coils and to compare the results with those
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Furthermore, we investigated whether aneurysm sac
volumetric analysis and other anatomical characteristics
identiﬁed on the preoperative computed tomography
(CT) scan could be reliable predictors of the efﬁcacy of
embo-EVAR in the prevention of EII.METHODS
Patients. A retrospective review was performed of all
consecutive patients admitted to the Clinic of Vascular and
Endovascular Surgery of Padova University who underwent
EVAR for infrarenal AAAs according to the device’s instruc-
tions for use between 2008 and 2011. From January 2008 to
December 2009, 83 patients underwent standard EVAR
(group A), and from January 2010 to October 2011, all
patients (n ¼ 79) eligible for EVAR underwent contempo-
rary aneurysm sac embolization with a standard dose of coils
and ﬁbrin glue (group B). Informed consent require-
ments were waived for this study, which was approved by
the Institutional Clinical Ethics Committee. Demographics,
preoperative characteristics, perioperative outcomes, and
follow-up data were obtained through review of patients’
medical records, pre- and postoperative CT angiograms,
and invasive diagnostic studies.
Inclusion and exclusion criteria. In both groups A
and B, only patients anatomically suitable for EVAR with
infrarenal AAAs were included. All EVAR patients who
underwent associated complex procedures such as chimney
grafts and branched and fenestrated grafts were excluded.
All commercially available aortobifurcated endografts were
included in this study, whereas aortouniliac and tubular
grafts and the double-barrel technique were not included.
Urgent or emergent EVAR procedures were excluded
from this study.
Treatment and deﬁnitions. Since January 2010 at
our institution, to prevent EII, EVAR has been performed
in association with aneurysm sac embolization. Our
protocol, which applied only to group B, is based on injec-
tion of a “standard” dose of material. The required dose of
ﬁbrin sealant to ﬁx a 16-cm2 surface is about 5 mL.
However, its use as an injectable matrix for aneurysm sac
embolization represents an off-label application. Previous
reports describe variable doses of both ﬁbrin glue (from
5 to $10 mL) and platinum coils (from 1 to $3) based on
aneurysm maximum diameter or persistence of an EII at
the ﬁnal intraoperative angiogram.7,8 On the basis of this
previous experience, we planned to use 5 mL ﬁbrin glue
(Tissucol; Baxter Hyland Immuno AG, Vienna, Austria)
and three coils (MReye Embolization Coil, IMWCE-35-
10-20; Cook Medical, Limerick, Ireland) during EVAR
independent of preoperative aneurysm dimensions and
anatomical characteristics. Our choice to use MReye coils,
instead of the formerly used platinum coils, was based on
the potential for minor scatter artifacts in the CT angio-
gram in the immediate vicinity of the coil and guaranteed
better detection of eventual endoleak during follow-up
(Fig 1, A and B).Operative comorbidity risk was evaluated using the
Society for Vascular Surgery comorbidity grading system9
and the American Society of Anesthesiologists score. Early
outcomes (#30 days from surgery) were evaluated using
comparisons of periprocedural data and associated mor-
bidity and mortality between the two groups. In accordance
with the current standard report for EVAR,10 primary clin-
ical success is deﬁned as absence of aneurysm-related death,
aneurysm rupture, conversion to open surgery, and sec-
ondary endovascular or surgical procedures.
For all patients in both groups, aneurysm sac maximum
diameter and volume were calculated pre- and postsurgery.
Aneurysm sac volume was calculated on 1-mm-thin slices
of CT angiograms using Osirix Pro 4.0 software. One
trained medical doctor manually tracked regions of interest
of the aneurysm external wall every 8 mm from axial cuts.
Subsequently, the software was asked to generate missing
regions of interest and compute aneurysm sac volume
intended in cubic centimeters (Fig 2, A and B). To identify
all minimal modiﬁcations of aneurysm volume between the
pre- and postoperative CT angiograms and to ensure
homogeneous measurement, the calculation was per-
formed, by deﬁnition, only for the infrarenal abdominal
aorta starting below the lowest renal artery and ending at
the aortic bifurcation. For three-dimensional volume
change, 5% or more was considered signiﬁcant on the basis
of Society for Vascular Surgery reporting standards.9,10
Preoperative CT angiogram anatomic factors including
patency of the inferior mesenteric artery (IMA) or paired
lumbar arteries and presence of accessory renal arteries
were also evaluated. Furthermore, quantity of sac thrombus
was evaluated and classiﬁed according to the percentage of
aneurysm sac volume (0%-25%, 26%-50%, 51%-75%). All
these parameters were evaluated separately and combined
in the multivariate analysis to determine any association
with EII.
The same two operators who have much experience in
EVAR performed the procedure for both groups routinely.
Follow-up was performed in all patients in both groups
by obtaining contrast CT angiograms at approximately 3, 6,
and 12 months and yearly after that. Average length of
follow-up was 2 years 5 months (range, 6 months to 4 years
4 months), with mean follow-up periods of 3½ years for
group A ( 3.16 1.4) and 1½ years for group B (1.16 0.7).
The deﬁnition “freedom from reintervention” was
applied to those patients who, during their follow-up,
did not have an EII or had an EII that did not require addi-
tional procedures. Indications for reintervention related to
the presence of an EII were >5-mm increase in maximum
diameter of the aneurysm sac diameter within two consec-
utive CT angiograms on follow-up and persistent EII (EII
on three or more consecutive CT angiograms during
follow-up) with any increase in aneurysm sac diameter.
Operative technique. This technique was intended
for group B only. Endoluminal access to the aorta was
gained through a center puncture with an 18-gauge nee-
dle in both common femoral arteries and placement of
a 10F sheath over the wire. A second unilateral puncture in
Fig 2. A preoperative analysis of aneurysm sac volume with Osirix
Pro 4.0 software. A, After selection of regions of interest of the
external aortic wall at axial cuts. B, Volume rendering with values
obtained in cubic centimeters.
Fig 1. Axial computed tomography (CT) angiogram images of aortic aneurysm sacs after endovascular aneurysm repair
(EVAR) with aneurysm sac embolization using (A) Tornado MReye coils and (B) platinum coils.
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10F sheath, and a standard J 0.035-inch guidewire
advanced under ﬂuoroscopy to the AAA sac. Subsequently,
a 23-cm-long 5F Brite Tip introducer was advanced over
the wire. At this point, a standard EVAR was performed
over the wires placed through the bilateral femoral artery
access.
Once the endograft was completely deployed and the
aneurysm excluded, three Tornado coils, 35, 10, and 20
mm (Cook Medical, Bloomington, Ind), were advanced
into the sac through a 5F catheter via the 5F introducer.
Subsequently, the catheter was replaced with a 35-cm-
long Duplocath catheter (Baxter International, Deerﬁeld,
Ill) connected to a Duployect syringe clip; this was fedinto the introducer until it reached the aneurysm sac. At
this point, to prevent distal embolization of the ﬁbrin
glue, two noncompliant balloons were inﬂated on both
iliac graft branches, and a total of 5 mL of glue was injected
into the aneurysm sac through the two-way catheter. After
approximately 40 seconds, the balloons were deﬂated, the
Duplocath catheter was removed, and the ﬁnal angiogram
was obtained to verify sac thrombosis and document even-
tual residual endoleak.
Intraoperative and postoperative therapy was the same
for both groups; in particular, the dose of anticoagulant
during the procedure was 5000 USP heparin units given
by endovenous infusion. From the ﬁrst postprocedural
day, patients were maintained on single antiplatelet therapy.
Statistical analysis. Means and standard deviations of
aneurysm sac volume before and after surgery were
compared between the two procedures by two-sample
t-test. Pearson, c2, and Fisher exact tests were used for
analysis of categorical variables. Kaplan-Meier freedom
from reintervention was estimated, and the log-rank
P value was used to compare the two procedures. The
multiple logistic regression model was used to identify
independent predictors of EII. P < .05 was used to
determine statistical signiﬁcance.RESULTS
Age was similar for patients in group A (70.7 6 7.2
years) and group B (71.2 6 6.1 years; P ¼ .95), as were
the proportions of patients aged <60 years at the time of
surgery (P ¼ 1.0). The majority of patients in both groups
were male (88% and 91%, respectively; P ¼ .43) and the
two groups were also similar in terms of cardiovascular risk
factors (Table I), anesthesiology (American Society of Anes-
thesiologists score; P ¼ .75), and perioperative risk assess-
ment (Society for Vascular Surgery sum score; P ¼ .96).
Mean preoperative aneurysm diameter was similar for
the two groups (5.7 6 1.1 cm vs 5.8 6 0.9; P ¼ .94), as
was aneurysm volume (144 6 97 vs 128 6 68; P ¼ .89).
Of the anatomical preoperative characteristics identiﬁed
on the preoperative CT angiogram, only the proportion
of patent IMA was signiﬁcantly higher in group B than in
group A (83% vs 70%; P ¼ .04); no differences were
Table II. Preoperative aneurysm sac characteristics and
anatomical spectrum for the 162 patients with infrarenal
aortic abdominal aneurysms who underwent standard
EVAR (group A) and EVAR with aneurysm sac
embolization (group B)
Group A
(n ¼ 83)a
Group B
(n ¼ 79)a
P
value
Aneurysm sac characteristics
Volume, cm3 144 6 97 128 6 68 .89
Diameter, cm 5.7 6 1.1 5.8 6 0.9 .94
Anatomical spectrum
Patent inferior mesenteric
artery
58 (70) 66 (83) .04b
Patent lumbar artery pairs
1 pair 21 (25) 18 (23) .71
2 pairs 40 (48) 37 (47) .87
$3 pairs 22 (26) 24 (30) .6
Accessory renal arteriesc 2 (2) 3 (4) .67
Percentage of thrombus
volume
0%-25% 20 (24) 19 (24) .63
26%-50% 46 (55) 48 (60) 1.0
51%-75% 17 (20) 12 (15) .52
Other concomitant aneurysms
Associated monolateral
iliac aneurysm
6 (7) 5 (6) 1.0
Associated bilateral iliac
aneurysm
1 (1) — —
Iliac aneurysm diameter,
mm
2.46 6 0.2 2.43 6 0.3 .93
EVAR, Endovascular aneurysm repair.
aData presented as the mean 6 standard deviation or number (%).
bStatistically signiﬁcant.
cAccessory renals arising from aneurysm sac or required to be covered by the
endograft.
Table I. Demographics, cardiovascular risk factors, and
perioperative risk assessment in the 162 patients who
underwent standard EVAR (group A) and EVAR with
aneurysm sac embolization (group B)
Group A
(n ¼ 83)a
Group B
(n ¼ 79)a
P
value
Demographics
Age, years 70.7 6 7.2 71.2 6 6.1 .95
Age <60 years 3 (4) 2 (3) 1.0
Male gender 73 (88) 72 (91) .43
Cardiovascular risk factors
BMI, kg/m2 27.6 6 4.5 28.1 6 5.0 .94
Hypertension 66 (79) 64 (81) .85
Diabetes 8 (10) 9 (11) .80
Smokingb 42 (51) 49 (62) .15
Coronary artery disease 41 (49) 46 (58) .03c
History of CABG /PTCA 21 (25) 24 (30) .48
Chronic heart failure 3 (4) 2 (3) 1.0
Ejection fraction <45% 7 (8) 11 (14) .32
CRI (Cr > 1.5 mg/dL) 18 (22) 18 (23) .5
Dialysis 1 (1) 1 (1) .49
COPD 15 (18) 18 (23) .55
Home oxygen therapy 2 (2) 3 (4) .67
Perioperative risk assessment
ASA score 2.4 6 0.5 2.6 6 0.4 .75
SVS cardiac score 0.91 6 0.89 0.81 6 0.94 .93
SVS pulmonary score 0.57 6 0.85 0.48 6 0.82 .94
SVS renal score 0.31 6 0.64 0.28 6 0.57 .97
SVS sum score 0.85 6 0.44 0.82 6 0.46 .96
ASA, American Society of Anesthesiologists; BMI, body mass index;
CABG/PTCA, coronary artery bypass graft/percutaneous transluminal
coronary angioplasty; COPD, chronic obstructive pulmonary disease; Cr,
creatinine; CRI, chronic renal insufﬁciency; EVAR, endovascular aneurysm
repair; SVS, Society for Vascular Surgery.
aData presented as the mean 6 standard deviation or number (%).
bIncludes current and former smokers.
cStatistically signiﬁcant.
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or accessory renal arteries (Table II).
The mean duration of the embolization procedure was
14 6 3 minutes in group B. This time did not modify
the overall operative time between the two groups
(185 6 52 minutes vs 179 6 49 minutes; P ¼ .92). Intra-
operatively, a signiﬁcantly increased number of patients
underwent general anesthesia in group B than in group A
(75% vs 54%; P ¼ .008), whereas there were no differences
in requirements for transfusion of blood products (446 6
120 vs 483 6 133; P ¼ .83). A smaller number of Cook
Zenith (Cook Medical) (P ¼ .02) and larger number of
Jotec E-vita (Jotec, Hechingen, Germany) (P ¼ .005)
abdominal endografts were implanted in group B than in
group A, whereas no differences were reported between
the groups in the number of additional intraoperative endo-
vascular procedures (Table III). No statistically signiﬁcant
differences were found in the distribution of frequency of
EII among the different types of grafts during follow-up at
3, 6, 12, and 18 months. In particular, the frequency of
EII at the ﬁrst CT angiogram follow-up ranged from 20%
to 26% for the four most frequently used endografts in
group A (Cook, 22%, Gore, 26%, Medtronic, 20%, Jotec,20%) and from 8% to 14% in group B (Cook, 8%, Gore,
11%, Medtronic, 12%, Jotec, 14%).
Interestingly, even though the number of EIIs de-
tected at the ﬁnal intraoperative angiogram was lower in
group B (15% vs 22%), the difference was not statistically
signiﬁcant (P ¼ .31).
No differences were reported between the two
groups in terms of major medical or surgical complica-
tions within 30 days (Table IV). Technical success was
100% for both groups, and no aneurysm ruptures or
deaths were reported in this series; in particular, all
embo-EVAR procedures in group B were successful.
The ﬁrst CT angiogram obtained during follow-up
(within 30 days and 3 months) showed a signiﬁcantly
higher rate of EIIs in group A than in group B (24% vs
10%; P ¼ .02). The descriptive analysis of freedom
from EII illustrated in Fig 3 shows that group B had
signiﬁcantly higher success rates at 3 and 6 months
(P ¼ .02 and .03, respectively), but this was not borne
out during midterm follow-up (at 18 months; P ¼ .32).
During midterm follow-up (18 months), spontaneous
EII resolution occurred in 65% of patients in group A
and 79% in group B (P ¼ 1.0), whereas sac volume
Table IV. Early outcomes (#30 days after surgery) in
the 162 patients with infrarenal abdominal aortic
aneurysms treated with standard EVAR (group A) and
EVAR with aneurysm sac embolization (group B)
Outcomes (#30 days)
Group A
(n ¼ 83)a
Group B
(n ¼ 79)a
P
value
Medical outcomes
Major cardiacb 1 (1) 0 (—) .48
Respiratory failurec 1 (1) 1 (1) .49
Dialysis 0 (—) 0 (—) —
Death 0 (—) 0 (—) —
Surgical outcomes
Technical success 83 (100) 79 (100) —
Primary clinical success 78 (94) 75 (95) 1.0
Rupture 0 (—) 0 (—) —
Conversion 0 (—) 0 (—) —
Related death 0 (—) 0 (—) —
Early additional reinterventiond 5 (6) 4 (5) 1.0
Endoleaks
Type IA 1 (1) 0 (—) .48
Type IB 2 (2) 2 (2) .61
Type II 0 (—) 0 (—) —
Arterial femoral accesse 1 (1) 2 (2) 1.0
Limb ischemia/thrombosis 1 (1) 0 (—) .48
Distal embolization 0 (—) 0 (—) —
EVAR, Endovascular aneurysm repair.
aData expressed as the number (%).
bIntraoperative or perioperative major cardiologic event that required
intervention (cardiac massage, coronary artery bypass grafting, percutaneous
transluminal angioplasty, pacemaker implantation).
cPulmonary embolism or severe respiratory distress.
dRequiring surgical or endovascular additional reintervention within 30
days.
eIntended as bleeding or arterial wall dissection in the site of puncture
requiring surgical revision.
Table III. General operative and procedural information
by standard EVAR (group A) and EVAR with aneurysm
sac embolization (group B)
Group A
(n ¼ 83)a
Group B
(n ¼ 79)a
P
value
Operative data
General anesthesia 45 (54) 59 (75) .008b
Transfusion, mL 446 6 120 483 6 133 .83
Operative time, minutes 185 6 52 179 6 49 .92
Radiation exposure, minutes 26 6 5.2 25 6 7.3 .85
Length of stay, days
Intensive care unit 0.8 6 1.9 0.9 6 2.1 .97
Hospital 3.6 6 0.7 3.1 6 0.9 .65
Procedural data
Type of endograft
Cook, Zenith 49 (59) 34 (43) .02b
Gore, Excluder 19 (23) 20 (25) .85
Medtronic, Endurant 10 (12) 9 (11) 1.0
Jotec, E-vita Abdominal 5 (6) 17 (21) .005b
Vascutek, Anaconda 1 (1) — —
Embolization
Fibrin glue, mL — 5 —
Coils — 3 —
Additional endovascular
procedures
Proximal cuff 7 (8) 3 (4) .16
Distal iliac extension 3 (4) 1 (1) .62
Type II endoleaks at ﬁnal
angiogram
18 (22) 12 (15) .31
EVAR, Endovascular aneurysm repair.
aData are presented as the mean 6 standard deviation or number (%).
bStatistically signiﬁcant.
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(P ¼ .63). The overall difference in mean sac volume
shrinkage was similar for the two groups (27 6 12 cm3
vs 25 6 12 cm3; P ¼ .19).
In the Kaplan-Meier estimates at 18 months for
freedom from reintervention (Fig 4), group A had a signif-
icantly lower rate than group B (93% vs 99%; P ¼ .03). In
particular, during this period, ﬁve patients in group A
underwent six reinterventions: two patients underwent
coil embolization for patent inferior mesenteric artery,
with a repeated procedure in one of the two after 6
months; and three patients underwent coil embolization
of patent lumbar arteries. In group B, only one patient
(1%) underwent coil embolization of a couple of patent
sacral arteries 10 months after EVAR. In both groups,
the indication for reintervention was in all cases the pres-
ence of an EII with aneurysm sac growth >5 mm.
In our institution, the cost for a single patient emboliza-
tion during EVAR with this technique was calculated to be
z607á ($800), whereas the institutional reimbursement
expenses for a secondary reintervention for embolization
with coils of an EII after EVAR is z9.000á ($11,800).
Considering that during follow-up, six reinterventions
were performed in group A and sac embolization in all
79 patients and reintervention in only one patient in group
B, the total costs were z54.000á ($71,000) for group A
and 57.000á ($75,000) for group B.We carefully explored multivariate modeling for EII,
which showed that the only reliable independent
predictor of EII was preoperative aneurysm sac volume
>125 cm3 (odds ratio [OR], 4.0; 95% conﬁdence interval
[CI], 1.5-10.5; P ¼ .005); there was only a slight trend
toward preoperative aneurysm maximum diameter >5.7
cm being a predictive factor (OR, 2.4; 95% CI, 0.9-6.0;
P ¼ .054). Interestingly, even though a signiﬁcantly
larger number of IMAs were patent preoperatively in
group B than in group A, this was not a positive predictor
of EII (P ¼ .65).
Presence of thrombus as a percentage of volume and
presence of thrombus as the number of patent branches,
both separately and combined, did not appear to be a reli-
able predictor (Table V).DISCUSSION
The approach to EII changed dramatically over time;
10 years ago, EIIs were treated much more frequently,
whereas recently, clinical evidence has conﬁrmed that
many EIIs are innocuous and only those causing persistent
sac enlargement deserve aggressive treatment. The litera-
ture reports a secondary intervention success rate of
Fig 4. Kaplan-Meier curve for freedom from type II endoleak
(EII)-related reintervention during early and midterm follow-up
in groups A and B. SE, Standard error.
Table V. Final model of multiple logistic regression for
preoperative aneurysm sac dimensional characteristics and
anatomical spectrum in relation to EIIs
OR Inferiora Superiora
P
value
Group B
Patent inferior mesenteric
artery
.7 .2 2.5 .657
Patent lumbar artery pairs — — — .809
Patent accessory renals 2.1 .3 13.1 .409
Percentage of thrombus
volume
— — — .421
Group A
Patent inferior mesenteric
artery
.6 .2 2.1 .472
Patent lumbar artery pairs — — — .811
Patent accessory renal arteries 2.9 .5 18.7 .249
Percentage of thrombus
volume
— — — .396
Groups A and B 3.3 1.3 8.4 .012b
Maximum sac diameter
>5.7 cm
2.4 .9 6.0 .054
Sac volume >125 cm3 4.0 1.5 10.5 .005b
CI, Conﬁdence interval; EIIs, type II endoleaks; OR, odds ratio.
a95% CI for OR.
bStatistically signiﬁcant.
Fig 3. Descriptive analysis of freedom from type II endoleaks
(EIIs) during early and midterm follow-up in groups A and B.
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be surgical conversion.
Recently, on the basis of different experience, there has
been a trend toward preventing EIIs instead of treating
their complications after they develop. Brenes et al12 re-
ported laparoscopic IMA ligation before EVAR; Muthu
et al13 have described routine intraoperative selective
IMA embolization and thrombin injection into the aneu-
rysm sac just before EVAR.
Zanchetta et al14 showed that the injection of ﬁbrin
glue into the aneurysm sac during EVAR signiﬁcantly
reduces EIIs compared with standard EVAR. This group
reported further experience using variable doses of ﬁbrin
glue in association with coil embolization,7 with a signiﬁ-
cant reduction in EIIs compared with standard EVAR
(hazard ratio, 0.13; 95% CI, 0.05-0.36; P < .0001). A
subsequent study by Pilon et al,8 using both ﬁbrin glue
and coils, reported a comprehensive reduction in health
care costs in patients who underwent EVAR plusembolization compared with those who underwent stan-
dard EVAR. In our opinion, the combination of ﬁbrin
glue and coils to facilitate aneurysm sac thrombosis and
prevent EII formation represents a valid method. We
decided to change our practice based on the fact that this
technique does not require selective cannulation and
embolization of side branches but only sac ﬁlling. These
changes do not interfere signiﬁcantly with the standard
EVAR procedure in terms of operative time, dose of
contrast used, and extremely higher costs related to adjunc-
tive microcather and coils to be used.
Currently, however, there is no reliable method for
predicting the exact amount of material to be injected
into the sac to effectively prevent EII. In previous reports,
the amount of material injected was usually $5 mL of
ﬁbrin glue and $1 coils. When the ﬁnal angiographic
control revealed the persistence of EII, the dose of material
was increased. The use of a “standard” dose of material
indicates, in our experience, that the procedure was safe
with no differences in peri- and postoperative morbidity
and mortality between the two groups analyzed.
During follow-up, we had a signiﬁcant reduction of
EIIs within only 3 months and at 6 months between the
two groups (P ¼ .02 and .03 respectively), whereas after
this period, the number of EIIs was still lower in group
B but did not reach statistical signiﬁcance. On the other
hand, freedom from reintervention was signiﬁcantly higher
in group B as compared with group A in the Kaplan-Meier
estimates at 18 months (P ¼ .03).
Sac volume analysis in patients with EIIs revealed that
the number of patients with increased volumes during
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940 Piazza et al April 2013follow-up was higher, although not signiﬁcantly (P ¼ .63),
in group A than in group B (25% vs 10%) even if not signif-
icant. Thus, we can assume that even in the presence of
similar percentages of EIIs, the patients who underwent
embo-EVARweremore protected from the insidious evolu-
tion of EII with sac expansion or endoleak persistence
that usually requires additional intervention. In addition,
after EVAR, EII embolization may not be effective, thus
secondary additional procedures may be required, as
occurred in one case in group A (20%). This ﬁnding is in
accordance with recent results published by Sarac et al,15
who reported a need for secondary embolization in 20% of
cases with a 5-year freedom from secondary embolization
of 76% (95% CI, 66%-86%).
We tried to determine if any of the known preoperative
CT angiogram morphological predictors16-18 of endoleak
could be useful in predicting the efﬁcacy of this technique.
In this regard, we believe that aneurysm dimensions are
strictly related to the amount of material needed.
The dimensions of aneurysm sacs have traditionally been
evaluated on the basis of maximum aneurysm diameter.
Recently, there have been several reports on the use of
volumetric analysis to better determine the dimensions of
aneurysm sacs.19 Cani20 showed that volume calculation,
which differs from maximum diameter calculation, is
a precise method for evaluating modiﬁcations of the aneu-
rysm sac independently from the operator. Furthermore,
Fillinger,21 in 2006, reported for the Pivotal Trial that
three-dimensional volume criteria detect aneurysm sac
enlargement during EVAR follow-up more frequently
and sooner than do standard diameter criteria.
Use of a maximum aneurysm diameter >5.7. cm to
predict EIIs after embo-EVAR did not attain statistical
signiﬁcance (P ¼ .054), although this may represent
a type II statistical error. Conversely, an aneurysm sac
volume >125 cm3 turned out to be a robust independent
predictor of EIIs, with an OR of 4.0 (P ¼ .005), indicating
that embo-EVAR is effective only for aneurysms with
preoperative volumes <125 cm3. This ﬁnding prompted
us to consider volume as the principal factor to be investi-
gated preoperatively to optimize the dose of material
injected and be effective in EII prevention.
Our study has some limitations that are worthy of
mention. This was a retrospective, nonrandomized study
in a small cohort of patients. Longer follow-up is ideal
and may produce data that could alter our current conclu-
sion. Unfortunately, this technique was recently developed
with no standardized indication yet and only a little expe-
rience reported in the literature. Nevertheless, we selected
all patients for a careful and complete follow-up with
adequate imaging, allowing robust assessment of early
and midterm outcomes. The homogeneity of the two
groups and the injection of a standard dose of material
for embolization could guarantee reliable ﬁndings.
Results of this study, even in the presence of a signiﬁ-
cant reduction in EII-related reintervention, still reveal
a moderate reduction in EII frequency, especially at the
midterm follow-up. A step forward in improving theefﬁcacy of this technique would be to limit its use only to
those patients at high preoperative risk of endoleaks and
to adjust the dose of material injected on the basis of
preoperative aneurysm volume.
CONCLUSIONS
To our knowledge, no other published study has
compared aneurysm sac embolization during EVAR using
a standard dose of ﬁbrin glue and coils with traditional
EVAR. Although further conﬁrmatory studies are needed,
this technique may be a safe and valid approach to prevent-
ing EIIs and their complications during short- and
midterm follow-up. More aggressive intraoperative embo-
lization should be considered for patients with a preopera-
tive aneurysm sac volume >125 cm3.
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